# TNC

Source: https://onco.cc/targets/tnc/  
OnCo record `tnc` (Target). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

TNC (Tenascin) is a gene that drives cell growth when it is altered. The public catalogues list it as a drug target, an oncogene driver, a tumour suppressor and a biomarker, and clinical evidence ties its variants to diagnosis, prognosis or drug response. Tied to Pancreatic ductal adenocarcinoma, Adrenocortical carcinoma, Bladder & urothelial cancer and 5 more.

## Summary

Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6.

CIViC holds 2 clinical evidence items and 0 assertions across 1 variant, naming Gemcitabine. IntOGen calls it a driver in 7 cohorts (5 activating, 2 loss-of-function), covering Adrenocortical Carcinoma, Acute Myeloid Leukaemia, Bladder/Urinary Tract, Lung Squamous Cell Carcinoma, Malignant Lymphoma, Neuroblastoma and others.

## Fields

- Kind: Target
- Last checked: 2026-09-23
- Also known as: tenascin C; Tenascin; MGC167029; DFNA56
- Tags: cancer-genes-wave
- Symbol: TNC
- Class: oncogene
- Biology: Extracellular matrix protein implicated in guidance of migrating neurons as well as axons during development, synaptic plasticity as well as neuronal regeneration. Promotes neurite outgrowth from cortical neurons grown on a monolayer of astrocytes. Ligand for integrins alpha-8/beta-1, alpha-9/beta-1, alpha-V/beta-3 and alpha-V/beta-6. In tumours, stimulates angiogenesis by elongation, migration and sprouting of endothelial cells. Location: Secreted, extracellular space, extracellular matrix (UniProt). Locus 9q33.1 (HGNC).
- Where found: Pancreatic ductal adenocarcinoma: CIViC evidence names this disease; Adrenocortical carcinoma: IntOGen driver in 1 cohort (ACC); Bladder & urothelial cancer: IntOGen driver in 1 cohort (BLADDER); Non-Hodgkin lymphoma: IntOGen driver in 1 cohort (MLYM); Ovarian cancer: IntOGen driver in 1 cohort (OVT); Acute myeloid leukaemia: IntOGen driver in 1 cohort (AML)

## Notes

- Written by scripts/fetch-cancer-genes.ts from CIViC, Open Targets, IntOGen, HGNC and UniProt; the function text is UniProt's, condensed and in UK spelling. Roles: CIViC lists 1 therapies; IntOGen calls it an activating (Act) driver in 5 cohorts; IntOGen calls it a loss-of-function (LoF) driver in 2 cohorts; CIViC holds 2 clinical evidence items on its variants. Evidence tier "clinical-evidence" is the strongest of those signals.
- Prevalence not recorded: none of the sources gives a positivity rate.

## Sources

- HGNC HGNC:5318: https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:5318
- UniProt P24821: https://www.uniprot.org/uniprotkb/P24821/entry
- NCBI Gene 3371: https://www.ncbi.nlm.nih.gov/gene/3371
- Ensembl ENSG00000041982: https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000041982

## Connected records

- collections: [CIViC](https://onco.cc/collections/civic/), [IntOGen](https://onco.cc/collections/intogen/)
- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [Adrenocortical carcinoma](https://onco.cc/cancers/adrenocortical/), [Bladder & urothelial cancer](https://onco.cc/cancers/urothelial/), [Neuroblastoma (paediatric)](https://onco.cc/cancers/neuroblastoma/), [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Ovarian cancer](https://onco.cc/cancers/ovarian/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)

---
JSON: https://onco.cc/api/v1/entities/tnc.json